Results 211 to 220 of about 633,561 (259)
Some of the next articles are maybe not open access.
Current Opinion in Hematology, 1998
Progress has been made in understanding BCR-ABL-positive leukemias. A new transcript (p230BCR-ABL) has been characterized that is associated with Ph-positive chronic neutrophilic leukemia. The ATM protein appears to be a regulator of ABL activity in response to irradiation damage.
M W, Deininger, J M, Goldman
openaire +2 more sources
Progress has been made in understanding BCR-ABL-positive leukemias. A new transcript (p230BCR-ABL) has been characterized that is associated with Ph-positive chronic neutrophilic leukemia. The ATM protein appears to be a regulator of ABL activity in response to irradiation damage.
M W, Deininger, J M, Goldman
openaire +2 more sources
Osteolysis in Chronic Myeloid Leukemia
Tumori Journal, 1978Four patients affected by chronic myeloid leukemia who developed osteolytic lesions in the course of the disease are described. According to the literature, the appearance of these alterations seems to signify an unfavorable prognosis, since they occur slightly before or even at the same time as the blastic transformation of the disease.
G. Lambertenghi-Deliliers +3 more
openaire +3 more sources
New England Journal of Medicine, 1999
Over the past twenty years, clinical and laboratory studies have led to important new insights into the biology of chronic myeloid leukemia. Basic science has defined the molecular pathogenesis of chronic myeloid leukemia (CML) as unregulated signal transduction by the Bcr-Abl tyrosine kinase.
openaire +2 more sources
Over the past twenty years, clinical and laboratory studies have led to important new insights into the biology of chronic myeloid leukemia. Basic science has defined the molecular pathogenesis of chronic myeloid leukemia (CML) as unregulated signal transduction by the Bcr-Abl tyrosine kinase.
openaire +2 more sources
Immunotherapy for Acute Myeloid Leukemia
Seminars in Hematology, 2015Despite longstanding efforts in basic research and clinical studies, the prognosis for patients with acute myeloid leukemia (AML) remains poor. About half of the patients are not medically fit for intensive induction therapy to induce a complete remission and are treated with palliative treatment concepts.
Lichtenegger, F.S. +3 more
openaire +3 more sources
Metabolomics in acute myeloid leukemia
Molecular Genetics and Metabolism, 2020Acute myeloid leukemia (AML) is a complex, heterogenous hematological malignancy caused by mutations in myeloid differentiation and proliferation. Response to therapy and long-term outcomes vary widely based on chromosomal and molecular aberrations. Many platforms have been used to characterize and stratify AML.
Anna V, Wojcicki +3 more
openaire +2 more sources
Current Opinion in Oncology, 1992
Chronic myeloid leukemia is a clonal myeloproliferative disorder of a pluripotent stem cell with a specific cytogenetic abnormality, the Philadelphia chromosome, involving myeloid, erythroid, megakaryocytic, B lymphoid, and sometimes T lymphoid cells but not marrow fibroblasts.
openaire +3 more sources
Chronic myeloid leukemia is a clonal myeloproliferative disorder of a pluripotent stem cell with a specific cytogenetic abnormality, the Philadelphia chromosome, involving myeloid, erythroid, megakaryocytic, B lymphoid, and sometimes T lymphoid cells but not marrow fibroblasts.
openaire +3 more sources
Current Opinion in Hematology, 1997
The molecular origin of the BCR-ABL chimeric gene is now reasonably well defined; a new breakpoint cluster region in the BCR gene, designated mu-bcr, has recently been identified. p210BCR-ABL binds with or phosphorylates a wide variety of intracellular proteins but the mechanism by which it exerts its oncogenic potential is not yet known.
openaire +2 more sources
The molecular origin of the BCR-ABL chimeric gene is now reasonably well defined; a new breakpoint cluster region in the BCR gene, designated mu-bcr, has recently been identified. p210BCR-ABL binds with or phosphorylates a wide variety of intracellular proteins but the mechanism by which it exerts its oncogenic potential is not yet known.
openaire +2 more sources
Vindesine effect in myeloid leukemia
Cancer Chemotherapy and Pharmacology, 1982Vindesine (VDS), a semisynthetic vinca alkaloid derivative, was given weekly at a dose of 3 mg/m2 as single-agent chemotherapy to seven patients with chronic myeloid leukemia (CML), 17 patients with chronic myeloid leukemia in blastic metamorphosis (CML/BM), and 12 patients with acute nonlymphocytic leukemia (ANLL).
M, Baccarani +3 more
openaire +2 more sources
JAMA
Importance Chronic myeloid leukemia (CML) has an annual incidence of 2 cases per 100 000 people and is newly diagnosed in approximately 9300 individuals per year in the US.
Elias, Jabbour, Hagop, Kantarjian
openaire +2 more sources
Importance Chronic myeloid leukemia (CML) has an annual incidence of 2 cases per 100 000 people and is newly diagnosed in approximately 9300 individuals per year in the US.
Elias, Jabbour, Hagop, Kantarjian
openaire +2 more sources
Immunotherapy of Acute Myeloid Leukemia
Current Pharmaceutical Biotechnology, 2001Most patients with acute myeloid leukemia (AML) respond initially to combination chemotherapy but later relapse. These patients often die from progressive disease or toxicities of further chemotherapy. At relapse, the patients' blasts are usually resistant to the drugs to which the patient has been exposed and frequently to other cytotoxic agents as ...
A E, Frankel +3 more
openaire +2 more sources

